Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems
Medtronic Vascular · Decision date Oct 16, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-16 for supplement P160043/S096 to Medtronic Vascular's Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems, a coronary drug-eluting stent under product code NIQ in the cardiovascular specialty. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier.
The recorded statement describes changing the point of finished device test sample collection. This is a manufacturing and testing logistics change within the existing PMA, not a new approval of the stent system, and the source does not identify which facility, test, or sampling step is affected. No supporting documents were included, so the specific procedural details and any FDA review basis remain unknown.
Whether the revised collection point alters test representativeness or release criteria cannot be determined from the available fields, which is the main unresolved question for quality and regulatory readers.
FDA approval order statement
changing the point of finished device test sample collection
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160043/S096
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular
- Product code
- NIQ
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Medtronic Vascular
- Product code
- NIQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160043. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160043 · Original PMA
RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM
P160043/S096 received
Application receipt date recorded by FDA.
P160043/S096 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P160043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA approval | Apr 28, 2017 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
| Biotronik AG | PMA approval | Feb 22, 2019 | FDA | |
| Abbott Vascular | PMA approval | Nov 1, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P160043/S096
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



